Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (836)	11/20/1998 3:26:00 PM
From: FNS	Read Replies (1) \| Respond to of 965

Thanks, Peter, for the news...i had heard something about side effects but didn't give it much credence. Now I know. Got out recently and have been kicking myself for not getting back in at 47...now I'll surely take my time. <<The reports of adverse reactions in retreated Crohns patients are probably just a reflection of an impurity in the original formulation (see the ISIS thread for details),>> Won't the FDA have to re-inspect the process before CNTO resumes distribution...will they need to do a Ph-IV trial??? FNS